The Dose Reduction in Schizophrenia (DORIS) study: A final report

Schizophrenia Research

Volumn 23, Issue 1, 1997, Pages 31-43

  Hirschowitz, J ^a,b   Hitzemann, R ^a,c   Piscani, K ^a,c   Burr, G ^a,c   Frecska, E ^a,c,d   Culliton, D ^b   Mann, M ^a   Curtis, C ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d Pilgrim State Hospital   (United States)

Author keywords

bromocriptine; dose reduction; growth hormone; haloperidol; positive symptoms; psychosis; schizophrenia

Indexed keywords

BENZATROPINE; BROMOCRIPTINE; DIPHENHYDRAMINE; GROWTH HORMONE; HALOPERIDOL; LORAZEPAM;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE; DRUG TOLERANCE; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; BRAIN; BROMOCRIPTINE; CHRONIC DISEASE; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALOPERIDOL; HUMAN GROWTH HORMONE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0031575427     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(96)00074-6     Document Type: Article

References (39)

1. Andreasen, N.C., Flaum, M. and Arndt, S. (1992) The Comprehensive Assessment of Symptoms and History (CASH): An instrument for assessing diagnosis and psychopathology. Arch. Gen. Psychiatry 49, 615-623.
2. Baron, J.C., Martinot, J.L., Cambon, H., Boulenger, J.P., Poirier, M.F., Caillard, V., Blin, J., Huret, J.D., Loc'h, C. and Maziere, B. (1989) Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: Correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmocology 99, 463-472.
3. Coppens, H.J., Slooff, C.J., Paans, A.M., Wiegman, T., Vaalburg, W. and Korf, J. (1991) High central D2-dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy-resistant schizophrenic patients. Biol. Psychiatry 29, 629-634.
4. Creese, I. (1987) Biochemical properties of CNS dopamine receptors. In: H.Y. Meltzer (Ed.), Psychopharmacology: The Third Generation of Progress. Raven Press, New York, pp. 257-264.
5. Deniker, P. (1989) From chlorpromazine to tardive dyskinesia: Brief history of the neuroleptics. Psychiatr. J. Univ. Ott. 14(1), 253-259.
6. Farde, L., Nordstrom, A.-L., Wiesel, F.-A., Pauli, S., Halldin, C. and Sedvall, G. (1992) PET-analysis of central D1-and D2-dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: Relation to extrapyramidal side effects. Arch. Gen. Psychiatry 49, 538-544.
7. Goldberg, S.C. (1985) Negative and deficit symptoms in schizophrenia to respond to neuroleptic. Schizophr. Bull. 11, 453-456.
8. Haase, H.J. (1961) Extrapyramidal modification of fine movements: A 'conditio sine qua non' of the fundamental therapeutic action of neuroleptic drugs. In: J.M. Bordeleau (Ed). Systeme Extrapyramidal et Neuroleptiques. Editions Psychiatriques, Montreal, pp. 329-353.
9. Hirschowitz, J., Hitzemann, R., Burr, G. and Schwartz, A. (1991) A new approach to dose reduction in chronic chizophrenia. Neuropsychopharmacology 5, 103-113.
10. Hirschowitz, J., Zemlan, F.P., Hitzemann, R.J., Fleischmann, R. and Garver, D.L. (1986) Growth hormone response to apomorphine and diagnosis: A comparison of three diagnostic systems. Biol. Psychiatry 21, 445-454.
11. Inderbitzin, L.B., Lewine, R.R.J., Scheller-Gilkey, G., Swofford, C.D., Egan, G.J., Gloersen, B.A., Vidanagama, B.P. and Waternaux, C. (1994) A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients. Am. J. Psychiatry 151, 1753-1759.
12. Janicak, P.G., Javaid, J.I., Sharma, R.P., Leach, A., Dowd, S., Blake, L. and Davis, J.M. (1994) Random assignment to three haloperidol plasma levels for acute psychosis. Biol. Psychiatry 35, 666.
13. Kane, J., Honigfeld, G., Singer, J., Meltzer, H. and the Clozaril Collaborative Study Group (1988) Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch. Gen, Psychiatry 45, 789-796.
14. Kay, S.R., Fiszbein, A. and Opler, L.A. (1987) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 13, 261-276.
15. Keefe, R.S.E., Mohs, R.C., Losonczy, M.F., Davidson, M., Siverman, J.M., Kendler, K.S., Nora, R., Horvath, T.B. and Davis, K.L. (1987) Characteristics of very poor outcome schizophrenia. Am. J. Psychiatry 144, 889-895.
16. Krakowski, M.I., Kunz, M., Czobor, P. and Valavka, J. (1993) Long-term high-dose neuroleptic treatment: Who gets it and why? Hosp. Community Psychiatry 44, 640-644.
17. Leblanc, G., Cormier, H., Gagne, M.A. and Vaillancourt, S. (1994) Effects of neuroleptic reduction in schizophrenic outpatients receiving high doses. Can. J. Psychiatry 39(4), 223-229.
18. Levinson, D.F., Simpson, G.M., Singh, H., Yadalam, K., Jain, A., Stephanos, M.F. and Silver, P. (1990) Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment. Arch. Gen. Psychiatry 47, 761-768.
19. Liberman, R.P., Van Putten, T., Marshall Jr., B.D., Mintz, J., Bowen, L., Kuehnel, T.G., Aravagiri, M. and Marder, S.R. (1994) Optimal drug and behavior therapy for treatment-refractory schizophrenic patients. Am. J. Psychiatry 151, 756-759.
20. McEvoy, J.P., Hogarty, G. and Steingard, S. (1991) Optimal dose of neuroleptic in acute schizophrenia: A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch. Gen. Psychiatry 48, 739-745.
21. McEvoy, J.P., Stiller, R.L. and Farr, R. (1986) Plasma haloperidol levels drawn at neuroleptic threshold doses: A pilot study. J. Clin. Psychopharmacol. 6, 133-138.
22. Meltzer, H.Y. (1985) Dopamine and negative symptoms in schizophrenics critique of the type I-type II hypothesis. In: M. Alpert (Ed.), Controversies in Schizophrenia: Changes and Constancies. Guilford Press, New York, pp. 10-136.
23. Nordstrom, A.-L., Farde, L., Wiesel, F.A., Forslund, K., Pauli, S., Halldin, C. and Uppfelt, G. (1993) Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients. Biol. Psychiatry 33, 227-235.
24. 11C]raclopride binding in healty young adults and schizophrenic patients-reliability and age effects. Hum. Psychopharmacol. 7, 157-165.
25. Nyberg, S., Farde, L., Halldin, C., Dahl, M.-L. and Bertilsson, L. (1995) D2-dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am. J. Psychiatry 152, 173-178.
26. Reardon, G.T., Rifkin, A., Schwartz, A., Myerson, A. and Siris, S.G. (1989) Changing patterns of neuroleptic dosage over a decade. Am. J. Psychiatry 146, 726-729.
27. Rifkin, A., Doddi, S., Karagi, B., Borenstein, M. and Wachpress, M. (1991) Dosage of haloperidol for schizophrenia. Arch. Gen. Psychiatry 48, 166-170.
28. Schlyer, D.J., Volkow, N.D., Fowler, J.S., Wolf, A.P., Schiue, C.-H., Dewey, S.L., Bendriem, B., Logan, J., Raulli, R., Hitzemann, R., Brodie, J., Alavi, A.A. and MacGregor, R.R. (1992) Regional distribution and kinetics of haloperidol binding in human brain: A PET study with Seeman, P. and Van Tol, H.H. (1994) Dopamine receptor pharmocology. Trends Pharmacol. Sci. 15, 264-270.
29. Seeman, P., Chau-Wong, M., Tedesco, J. and Wong, K. (1975). Brain receptors for antipsychotic drugs and dopamine: Direct binding assays. Proc. Natl. Acad. Sci. USA 72, 4376-4380.
30. Shvartsburd, A., Kekirmenjian, H. and Smith, R.C. (1983) Blood levels of haloperidol in schizophrenic patients. J. Clin. Psychopharmacol. 3, 7-12.
31. Simpson, G.M., Lee, J.H., Zoubok, B. and Gardos, G. (1979) A rating scale for tardive dyskinesia. Psychopharmacology (Berlin) 64, 171-179.
32. Simpson, G.M. and Angus, J.W.S. (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. Suppl. 212, 11-19.
33. Smith, R.C. (1994) Lower-dose therapy with traditional neuroleptics in chronically hospitalized schizophrenic patients. Arch. Gen. Psychiatry 51, 427-429.
34. 18F]N-methylspiroperidol PET studies to measure changes in antipsychotic drug D2 receptor occupancy in schizophrenic patients. Biol. Psychiatry 23, 653-663.
35. Stone, C., Garver, D., Griffith, J., Hirschowitz, J. and Bennett, J. (1995). Haloperidol and psychosis: Further evidence of a lower dose-response threshold. Am. J. Psychiatry 152, 1210-1212.
36. Vadasz, C., Laszlovszky, I., De Simone, P.A. and Fleischer, A. (1992) Genetic aspects of dopamine receptor binding in the mouse and rat brain: An overview. J. Neurochem. 59, 793-808.
37. Van Putten, T., Marder, S.R. and Mintz, J. (1990). A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch. Gen. Psychiatry 47, 754-758.
38. Wirshing, W.C., Marder, S.R., Van Putten, T. and Ames, D. (1994) Acute treatment of schizophrenia. In: F. Bloom and D.J. Kupfer (Eds.), Psychopharmacology: The Fourth Generation of Progress. Raven Press, New York, pp. 1259-1266.
39. Wolkin, A., Brodie, J.D., Barouche, F., Rotrosen, J., Wolf, A.P., Smith, M., Fowler, J. and Cooper, T.B. (1989) Dopamine receptor occupancy and plasma haloperidol levels. Arch. Gen. Psychiatry 46, 482-484.